ResearcherSouthwest Medical UniversityActive in the last 2 years

Li Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7928-4170; OpenAlex author ID A5100762213. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 1 paper

Papers 2

Interaction between Maslinic acid and HSF1 enhances the ubiquitin degradation of HSF1, resulting in the inhibitory effect of pancreatic cancer. Co-author DOI 10.1007/s12672-025-02786-8 ↗
Active compounds of Caodoukou () inhibit the migration, invasion and metastasis of human pancreatic cancer cells by targeting phosphoinosmde-3-kinase/ protein … Co-author DOI 10.19852/j.cnki.jtcm.20230802.004 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xiukun Lin · 1 shared paper, 2025 · strength 0.27
- Paper Interaction between Maslinic acid and HSF1 enhances the ubiquitin degradation of HSF1, resulting in the inhibitory effe… DOI 10.1007/s12672-025-02786-8 ↗
Linlin Wang · 1 shared paper, 2025 · strength 0.27
- Paper Interaction between Maslinic acid and HSF1 enhances the ubiquitin degradation of HSF1, resulting in the inhibitory effe… DOI 10.1007/s12672-025-02786-8 ↗
Ammad Ahmad Farooqı · 1 shared paper, 2025 · strength 0.27
- Paper Interaction between Maslinic acid and HSF1 enhances the ubiquitin degradation of HSF1, resulting in the inhibitory effe… DOI 10.1007/s12672-025-02786-8 ↗
Yang Xiaohui · 1 shared paper, 2023 · strength 0.22
- Paper Active compounds of Caodoukou () inhibit the migration, invasion and metastasis of human pancreatic cancer cells by tar… DOI 10.19852/j.cnki.jtcm.20230802.004 ↗
Liu Minghua · 1 shared paper, 2023 · strength 0.22
- Paper Active compounds of Caodoukou () inhibit the migration, invasion and metastasis of human pancreatic cancer cells by tar… DOI 10.19852/j.cnki.jtcm.20230802.004 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.